Trial Profile
A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE).
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms BV-ICE
- 17 Aug 2023 Planned End Date changed from 30 Jun 2025 to 30 Sep 2025.
- 10 Jan 2023 Planned End Date changed from 10 Feb 2025 to 30 Jun 2025.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology